¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Human plasma protein fraction"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • human leukocyte antigen
    »ç¶÷¹éÇ÷±¸Ç׿ø
  • human leukocyte antigen complex
    »ç¶÷¹éÇ÷±¸Ç׿øº¹ÇÕü
  • human leukocyte antigen complex gene
    »ç¶÷¹éÇ÷±¸Ç׿øº¹ÇÕüÀ¯ÀüÀÚ
  • human menopausal gonadotropin
    »ç¶÷Æó°æ»ý½Ä»ùÀÚ±ØÈ£¸£¸ó, »ç¶÷Æó°æ¼º¼±ÀÚ±ØÈ£¸£¸ó
  • human papilloma virus
    »ç¶÷À¯µÎÁ¾¹ÙÀÌ·¯½º
  • human papilloma virus test
    »ç¶÷À¯µÎÁ¾¹ÙÀÌ·¯½º°Ë»ç
  • human placental lactogen
    »ç¶÷ŹÝÁ¥»ùÀÚ±ØÈ£¸£¸ó, »ç¶÷ŹݶôÅä°Õ
  • human rabies immune globulin
    »ç¶÷¹ÌÄ£°³º´¸é¿ª±Û·ÎºÒ¸°, »ç¶÷±¤°ßº´¸é¿ª±Û·ÎºÒ¸°
  • human T-cell lymphoma/leukemic virus
    »ç¶÷T¼¼Æ÷¸²ÇÁÁ¾/¹éÇ÷º´¹ÙÀÌ·¯½º
  • human T-cell lymphotropic virus
    »ç¶÷T¼¼Æ÷¸²ÇÁģȭ¹ÙÀÌ·¯½º
  • immune human serum globulin
    ¸é¿ª»ç¶÷Ç÷û±Û·ÎºÒ¸°
  • blood plasma
    Ç÷Àå
  • effective renal plasma flow
    À¯È¿ÄáÆÏÇ÷ÀåÀ¯·®, À¯È¿½ÅÀåÇ÷ÀåÀ¯·®
  • fresh frozen plasma
    ½Å¼±³Ãµ¿Ç÷Àå
  • interstitial plasma cell pneumonia
    »çÀÌÁúÇüÁú¼¼Æ÷Æó·Å, ÆóÆ÷ÀÚÃæÁõ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • antihemophilic plasma
    Ç×Ç÷¿ìº´Ç÷Àå
  • blood plasma
    Ç÷Àå
  • plasma cell
    ÇüÁú¼¼Æ÷
  • plasma coagulase
    Ç÷ÀåÀÀ°íÈ¿¼Ò
  • thromboplastin plasma component
    Æ®·Òº¸ÇÃ¶ó½ºÆ¾Ç÷À强ºÐ
  • plasma cell dyscrasia
    ÇüÁú¼¼Æ÷Áúȯ
  • effective renal plasma flow
    À¯È¿ÄáÆÏÇ÷Àå·ù·®
  • plasma exchange
    Ç÷À屳ȯ, Ç÷À屳ȯ¼ú
  • plasma volume expander
    ÀΰøÇ÷ÀåÁõ·®Á¦
  • plasma coagulation factor
    Ç÷ÀåÀÀ°íÀÎÀÚ
  • plasma thromboplastin factor
    Ç÷À寮·Òº¸ÇÃ¶ó½ºÆ¾ÀÎÀÚ
  • plasma cell granuloma
    ÇüÁú¼¼Æ÷À°¾ÆÁ¾
  • plasma hemoglobin
    Ç÷ÀåÇ÷¾×¼Ò
  • plasma iron
    Ç÷Àåö
  • plasma membrane
    ÇüÁú¸·
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Human immunodeficiency virus = HIV
    »ç¶÷¸é¿ª°áÇ̼º ¹ÙÀÌ·¯½º
  • Human placental lactogen
    ŹÝÀ¯¼±ÀÚ±Ø(÷ÃÚïêáàÍí©Ð½)È£¸£¸ó
  • antigen, human leukocyte (HLA)
    »ç¶÷ ¹éÇ÷±¸Ç׿ø, HLAÇ׿ø
  • hCG (Human chorionic gonadotropin)
    ÀÎÀ¶¸ð¸·¼º°í³ªµµÆ®·ÎÇÉ
  • human Herpesvirus 6 (HHV-6)
    Á¦6Çü »ç¶÷ Ç츣Æä½º¹ÙÀÌ·¯½º
  • human T cell leukemia virus type I
    Á¦1Çü »ç¶÷ T¼¼Æ÷¹éÇ÷º´¹ÙÀÌ·¯½º
  • human T cell leukemia virus type I
    Á¦1Çü »ç¶÷ T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • human T cell leukemia virus type II
    Á¦2Çü »ç¶÷ T¼¼Æ÷¹éÇ÷º´¹ÙÀÌ·¯½º
  • human T cell leukemia virus type II
    Á¦2Çü »ç¶÷ T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • human T lymphotrophic virus (HTLV)
    »ç¶÷ T ¸²ÇÁ±¸ ģȭ¼º ¹ÙÀÌ·¯½º
  • human T lymphotropic virus
    »ç¶÷<ÀÎ
  • human T-cell lymphotrophic virus
    Àΰ£ T¼¼Æ÷ ¸²ÇÁ ¿µ¾ç¼º ¹ÙÀÌ·¯½º
  • human acariasis
    ÀÎü³»Áøµå±âÁõ, ÀÎü³»°³¼±Ã溴(ìÑô÷Ò®ËÊàÈõùÜ»).
  • human bite
    »ç¶÷±³»ó(¡­Îáß¿).
  • human bite
    »ç¶÷±³»ó(¡­±³»ó).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • reducible fraction
    ¹Ì¾àºÐ¼ö(Ú±å³ÝÂâ¦).
  • reduction of fraction
    ¾àºÐ(å³ÝÂ).
  • regurgitant fraction
    ¿ª·ùºÐȹ.
  • renal fraction
    ½ÅºÐÀ².
  • tubular rejection fraction ratio
    ½Å¼¼´¢°ü°ÅºÎºÐȹ·ü.
  • volume fraction
    ¿ëÀûºÐȹ.
  • antigen, human leukocyte (HLA)
    »ç¶÷ ¹éÇ÷±¸Ç׿ø, HLAÇ׿ø
  • class I human leukocyte antigen
    Á¦ 1±Þ ÀÎü¹éÇ÷±¸Ç׿ø
  • class II human leukocyte antigen
    Á¦ 2±Þ ÀÎü¹éÇ÷±¸Ç׿ø
  • ecology, human
    Àΰ£»ýÅÂÇÐ.
  • hCG (Human chorionic gonadotropin)
    ÀÎÀ¶¸ð¸·¼º°í³ªµµÆ®·ÎÇÉ
  • hiv(human immunodeficiency virus)
    ÀÎü¸é¿ª°áÇ̹ÙÀÌ·¯½º(ìÑô÷Øóæ¹ÌÀù¹¡­)
  • human Herpesvirus 6 (HHV-6)
    Á¦6Çü »ç¶÷ Ç츣Æä½º¹ÙÀÌ·¯½º
  • human T cell leukemia virus type I
    Á¦1Çü »ç¶÷ T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • human T cell leukemia virus type I
    Á¦1Çü »ç¶÷ T¼¼Æ÷¹éÇ÷º´¹ÙÀÌ·¯½º
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • plasma lipoproteins
    Ç÷Àå(úìíì) ÁöÁú´Ü¹éÁú(ò·òõÓ±ÛÜòõ)
  • plasma membrane
    ¿øÇüÁú¸·(ê«û¡òõد)
  • plasma proteins
    Ç÷Àå ´Ü¹éÁú(úìíìÓ±ÛÜòõ)
  • plasma sol
    Á¹»ó(ßÓ) ¿øÇüÁú(ê«û¡òõ)
  • plasma-specific enzyme
    Ç÷À寝ÀÌ È¿¼Ò(úìíì÷åì¶ý£áÈ)
  • plasma thromboplastic factor
    Ç÷Àå Ç÷ÀüÇü¼ºÀÎÀÚ(úìíìúìîûû¡à÷ì×í­)
  • plasma thromboplastic factor B
    Ç÷Àå Ç÷ÀüÇü¼ºÀÎÀÚ B
  • plasma thromboplastin antecedent
    Ç÷Àå(úìíì) Æ®·Òº¸ÇÃ¶ó½ºÆ¾ Àü±¸¹°(îñÏÌÚª)
  • plasma thromboplastin component
    Ç÷Àå(úìíì) Æ®·Òº¸ÇÃ¶ó½ºÆ¾ ¼ººÐ(à÷ÝÂ)
  • plasma transferrin
    Ç÷Àå(úìíì) Æ®¶õ½ºÆä¸°
  • plasma transglutaminase
    Ç÷Àå(úìíì) Æ®¶õ½º±Û·çŸ¹Ì³×À̽º
  • separated plasma
    ºÐ¸®Ç÷Àå(ÝÂ×îúìíì)
  • true plasma
    ¼øÇ÷Àå(âíúìíì)
  • whole plasma
    ÀüÇ÷Àå(îïúìíì)
  • accelerator protein
    ÃËÁø´Ü¹éÁú (õµòäÓ±ÛÜòõ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
TPC thromboplastic plasma component; thyroid papillary carcinoma; total patient care; total plasma catec...
HSP Health Systems Plan; heat shock protein; hemostatic screening profile; Henoch-Schonlein purpura; her...
MAP malignant atrophic papulosis; mandibular angle plane; maturation-activated protein; maximal aerobic ...
MBP major basic protein; maltose-binding protein; management by policy; mannose-binding protein; mean bl...
RP radial pulse; radiopharmaceutical; rapid processing [of film]; Raynaud phenomenon; reactive protein;...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
EF Etiologic Fraction
FF Filtration Fraction
F Fraction
Fr. Fraction
F1 Fraction 1
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • class I human leukocyte antigen
    Á¦ 1±Þ ÀÎü ¹éÇ÷±¸ Ç׿ø
  • class II human leukocyte antigen
    Á¦ 2±Þ ÀÎü ¹éÇ÷±¸ Ç׿ø
  • enteric cytopathogenic human orphan virus
    ¿¡ÄÚ ¹ÙÀÌ·¯½º
  • human bite
    »ç¶÷ ±³»ó
  • human chorionic gonadotropin
    »ç¶÷ À¶¸ð¼º ¼º¼± ÀÚ±Ø È£¸£¸ó
    ÀÌ´Â glyco
  • human counter
    Àü½Å °è¼ö ÀåÄ¡
    µ¿ÀǾî=whole body counter.
  • human ecology
    Àΰ£ »ýÅÂÇÐ, Àηù »ýÅÂÇÐ
    Àΰ£°ú ȯ°æ°úÀÇ »óÈ£ ÀÛ¿ëÀ» ¿¬±¸ÇÏ´Â »ý¹°ÇÐÀÇ ÇÑ ºÐ¾ß.
  • human fetal membrane
    »ç¶÷ ÅÂ¾Æ ¸·
  • human genome
    Àΰ£ °Ô³ð
  • human growth hormone
    ¼ºÀå È£¸£¸ó
    ¼ºÀåÀ» ÃËÁøÇÏ´Â ¹°ÁúÀ» ÃÑĪÇϸç, ƯÈ÷ ³úÇϼöü Àü¿±¿¡¼­ ºÐºñµÇ´Â È£¸£¸óÀ» ¸»ÇÑ´Ù.
  • human histocompatibility antigen
    ÀÎü Á¶Á÷ ÀûÇÕ Ç׿ø
  • human immunodeficiency virus
    Àΰ£ ¸é¿ª °áÇÌ ¹ÙÀÌ·¯½º
  • human immunodeficiency virus infection
    Àΰ£ ¸é¿ª °áÇÌ ¹ÙÀÌ·¯½º °¨¿°
  • human leukocyte antigen-B27
    ÀÎü ¹éÇ÷±¸ Ç×ü-B27
    º¸Åë °­Á÷¼º ôÃß¿° ȯÀÚ¿¡¼­ ³ªÅ¸³ª´Â À¯Àü Ç¥½ÃÀÚ.
  • human menopausal gonadotropin
    Æä°æ ¿©¼º ¼º¼± ÀÚ±Ø È£¸£¸ó
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
granuloma, plasma cell, orbital A distinctive, chronic inflammatory reaction in the orbital tissues of the eye, of unknown aetiology, that may closely resemble a neoplasm and often becomes bilateral. Symptoms include exophthalmos and congestion of the lids with oedema. When limitation of ocular motility also occurs, it is sometimes called orbital myositis.
(12 Dec 1998)
granuloma, plasma cell, pulmonary A pseudotumour of the lung composed of inflammatory cells and showing complete maturity of fibroblastic components with a striking lack of mitosis. It is also called postinflammatory pseudotumour and pseudoneoplastic pneumonitis. (berardi, r.s. Et al. Inflammatory pseudotumours of the lung. Surg gynecol obstet 156:89-96, jan 83)
(12 Dec 1998)
collisionless plasma model <radiobiology> Model of a plasma in which the density is so low, or the temperature so high, that close binary (two-body) collisions have practically no significance (on certain timescales) because the time scales of interest are shorter than the collision time. Yields valid physical results for timescales much shorter than the average collision time in a real plasma.
(09 Oct 1997)
plasma <haematology> Acellular fluid in which blood cells are suspended. Serum obtained by defibrinating plasma (plasma derived serum) lacks platelet released factors and is less suitable to support the growth of cells in culture.
(13 Oct 1997)
plasma accelerator globulin <chemical> Heat- and storage-labile plasma glycoprotein which accelerates the conversion of prothrombin to thrombin in blood coagulation. Factor v accomplishes this by forming a complex with factor xa, phospholipid, and calcium (prothrombinase complex). Deficiency of factor v leads to owren's disease.
Chemical name: Blood-coagulation factor V
(12 Dec 1998)
plasma albumin <protein> The serum level of the low molecular protein albumin. Albumin, produced by the liver, plays an important role in maintaining plasma oncotic pressure. Normal serum albumin should be 3.5-5.0 grams per decilitre. Low serum albumin can be found in cases of liver disease and malnutrition.
(27 Sep 1997)
plasma cell <haematology> A terminally differentiated antibody forming and usually antibody secreting, cell of the B-cell lineage.
(18 Nov 1997)
plasma cell balanitis Benign circumscribed balanitis characterised microscopically by subepithelial plasma cell infiltration and clinically by small erythematous papular lesions.
Synonym: balanitis circumscripta plasmacellularis, balanitis of Zoon, Zoon's erythroplasia.
(05 Mar 2000)
plasma cell dyscrasia A diverse group of diseases characterised by the proliferation of a single clone of cells producing a monoclonal immunoglobulin or immunoglobulin fragment (a serum M component). The cells usually have plasma cell morphology, but may have lymphocytic or lymphoplasmacytic morphology. This group includes multiple myeloma, Waldenstrom's macroglobulinaemia, the heavy chain disease, benign monoclonal gammopathy, and immunocytic amyloidosis.
(05 Mar 2000)
plasma cell gingivitis Intense hyperaemic oedema and inflammation of the gingiva resulting from a hypersensitivity reaction. A dense plasma cell infiltrate is seen in the lamina propria.
Synonym: atypical gingivitis.
(05 Mar 2000)
plasma cell hepatitis <pathology> A type of chronic active hepatitis that results from circulating auto-antibodies and chronic inflammation of the liver.
Symptoms are those of chronic active hepatitis.
(27 Sep 1997)
plasma cell leukaemia An unusual disease characterised by leukocytosis and other signs and symptoms that are suggestive of leukaemia, in association with diffuse infiltrations and aggregates of plasma cells in the spleen, liver, bone marrow, and lymph nodes, and the presence of considerable numbers of plasma cells in the circulating blood; the total number of leukocytes in the latter may range from normal levels to 80,000 or 90,000 per cu mm, and 5 to 90% may be plasma cells; multiple myelomas are observed in some examples of plasma cell leukaemia, but discrete nodules are not formed in bone. Although there are other clinicopathologic differences in the two conditions, they may be phases of the same basic process.
(05 Mar 2000)
plasma cell mastitis A condition of the breasts characterised by tumourlike indurated masses containing numerous plasma cells, usually resulting from mammary duct ectasia; although clinically resembling malignant disease (attachment to skin and enlargement of axillary lymph nodes), it is not neoplastic.
(05 Mar 2000)
plasma cell myeloma Cells resemble mature or immature plasma cells with nuclei that appear cleaved or resemble immunoblasts. The tumour cells are CD19- , CD20- , CD22- and SIg- , but are also cIg+ and CD38+. The Ig heavy and light chain genes can be translocated or deleted. These neoplasms are often disseminated BM tumours of adults and progress to multiple myeloma.
(05 Mar 2000)
plasma cells Special white blood cells that produce antibodies.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • human potentials movement
    Àΰ£ ÀáÀç ´É·Â È¸º¹ ¿îµ¿(ÀÏÁ¾ÀÇ Áý´Ü ¿ä¹ýÀû ¼ö¾ç ¿îµ¿)
  • human power
    ÀÎÀû ÀÚ¿ø
  • human race
    Àηù 
  • human relations
    Àΰ£ °ü°è;´ëÀÎ °ü°è
  • human resource administration
    ÀÎÀû ÀÚ¿ø °ü¸®(Á¾¾÷¿øÀÇ °í¿ë,ÇØ°í,ºÒ¸¸ ó¸® µîÀÇ Àλç°ü¸®)
  • human rights
    (±âº»Àû)ÀαÇ
  • human rights diplomacy
    À뱂 ¿Ü±³(Jimmy Carter¹Ì±¹ Àü´ëÅë·É(1977-81)ÀÇ À뱂 ¿ËÈ£ ÃËÁøÀ» À§ÇÑ ¿Ü±³ ¹æÄ§)
  • human sciences
    Àι® °úÇÐ(ÀηùÇÐ,¾ð¾îÇÐ,»çȸÇÐ,¹®ÇÐ,½É¸®ÇÐ µîÀÇ ÃÑĪ)
  • human torpedo
    Àΰ£ ¾î·Ú(¸ñÇ¥ °¡±îÀ̱îÁö Àΰ£ÀÌ À¯µµÇÔ)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á